BNP and NT-proBNP Test: Diagnosing and Monitoring Heart Failure

BNP (B-type natriuretic peptide) and NT-proBNP are cardiac biomarkers secreted by the heart in response to increased wall stress and volume overload. They are the cornerstone blood tests for diagnosing acute heart failure in emergency settings, estimating prognosis, and guiding long-term management of patients with known heart failure. A BNP below 100 pg/mL effectively rules out heart failure as the cause of breathlessness with a negative predictive value exceeding 96%, while markedly elevated levels confirm the diagnosis and quantify severity. Understanding the differences between BNP and NT-proBNP — including their clearance mechanisms, half-lives, and diagnostic cutoffs — is essential for interpreting results correctly and avoiding common pitfalls such as false positives in kidney disease and false negatives in obese patients.

Table of Contents

1. Overview — What Is BNP and Why Does It Matter?
2. Biochemistry: How BNP and NT-proBNP Are Produced
3. Reference Ranges and Diagnostic Cutoffs
4. BNP vs. NT-proBNP: Choosing the Right Test
5. Using BNP to Diagnose Acute Heart Failure
6. Non-Heart-Failure Causes of Elevated BNP
7. When BNP Is Falsely Low
8. Prognostic Value and Serial Monitoring in Heart Failure
9. Key Research and Citations
10. Connections
11. Featured Videos

Overview — What Is BNP and Why Does It Matter?

BNP was originally isolated from porcine brain tissue in 1988 — hence "brain" natriuretic peptide — but its primary source in humans is the ventricular cardiomyocyte, not the brain. The "B-type" designation was later adopted to distinguish it from ANP (A-type, secreted by atria). When the walls of the heart ventricles are stretched by increased pressure or volume — as occurs in heart failure, cardiomyopathy, severe valve disease, or pulmonary hypertension — ventricular cells increase BNP gene transcription within minutes to hours, producing the prohormone proBNP-108.

BNP serves as the heart's emergency signal to the rest of the body. Its physiological actions are vasodilatory and natriuretic: it relaxes blood vessels, promotes sodium and water excretion by the kidneys, suppresses the renin-angiotensin-aldosterone system (RAAS), and inhibits sympathetic nervous system activation. In essence, BNP is the heart trying to reduce its own workload when it is under strain. Measuring circulating BNP levels gives clinicians a direct read on how much stress the heart is experiencing — even when other signs like edema or an audible third heart sound are absent or ambiguous.

From a clinical standpoint, BNP and NT-proBNP transformed emergency medicine when they were introduced in the early 2000s. Before these tests, distinguishing cardiac dyspnea from pulmonary dyspnea at the bedside required clinical gestalt, chest X-rays, and echocardiography — tools that are slow, operator-dependent, or unavailable after hours. A rapid BNP result available within 15 minutes of blood draw allowed ED physicians to triage dyspneic patients with unprecedented accuracy and speed.

Back to Table of Contents

Biochemistry: How BNP and NT-proBNP Are Produced

The BNP gene (NPPB, chromosome 1p36) encodes preproBNP-134, which is cleaved to proBNP-108 inside ventricular cardiomyocytes. When released into the circulation, proBNP-108 is cleaved by the serine protease corin and the metalloprotease furin into two fragments of unequal size and very different properties:

BNP-32 (the Active Hormone)

BNP-32 is the C-terminal 32-amino-acid fragment. It is biologically active, binding the natriuretic peptide receptor A (NPR-A) on vascular smooth muscle and renal tubular cells to produce its vasodilatory and natriuretic effects. BNP has a short plasma half-life of approximately 20 minutes. It is cleared primarily by two mechanisms: binding to natriuretic peptide clearance receptor (NPR-C), which internalizes and degrades it, and enzymatic cleavage by neprilysin (neutral endopeptidase), the same enzyme inhibited by sacubitril in the heart failure drug sacubitril/valsartan (Entresto). Because neprilysin degrades BNP, patients on sacubitril/valsartan have artificially elevated BNP levels — a critical clinical pitfall. Their NT-proBNP levels are unaffected and should be used for monitoring instead.

NT-proBNP (the Inactive Fragment)

NT-proBNP is the N-terminal 76-amino-acid fragment. It has no known intrinsic hormonal activity — it is a passive byproduct of BNP processing released in equimolar amounts to BNP. However, its longer plasma half-life of approximately 60–120 minutes makes it more stable in blood samples and allows it to accumulate to higher absolute concentrations than BNP in the same clinical setting. NT-proBNP is cleared almost exclusively by the kidneys (glomerular filtration), which explains why NT-proBNP values are disproportionately elevated in chronic kidney disease compared with BNP, and why age-stratified cutoffs are essential for NT-proBNP interpretation.

Stimulus-Response Kinetics

BNP gene transcription begins within 30 minutes of acute ventricular stretch. Measurable BNP rises in blood within 1–2 hours of an acute hemodynamic insult, making it highly responsive to acute cardiac decompensation. Conversely, BNP levels fall rapidly when the hemodynamic burden is relieved — for example, after aggressive diuresis in acute decompensated heart failure — making serial measurements useful for tracking treatment response. NT-proBNP has a longer plateau and decay curve due to its longer half-life, but also reflects real-time changes over a 24–48 hour window.

Back to Table of Contents

Reference Ranges and Diagnostic Cutoffs

BNP and NT-proBNP diagnostic cutoffs differ substantially. They are not interchangeable — each assay has its own validated thresholds, and switching between them mid-treatment without recalibration is a known source of clinical error.

BNP Cutoffs (European Society of Cardiology and Breathing Not Properly Trial)

NT-proBNP Cutoffs (Age-Stratified — ESC/PRIDE Study)

The single rule-out threshold for NT-proBNP (<300 pg/mL across all ages) reflects the test's superior negative predictive value when it is low. The rule-in thresholds rise with age because NT-proBNP increases physiologically with aging due to declining renal function and age-related cardiac structural changes, even in the absence of heart failure.

Obesity Adjustment

Both BNP and NT-proBNP are significantly lower in obese patients (BMI >30) even when heart failure is present. For BNP, a lower obesity-adjusted rule-out cutoff of approximately 54 pg/mL (rather than 100 pg/mL) has been proposed to maintain acceptable sensitivity. This is not universally standardized, but clinicians should have a high suspicion of HF in obese patients even with modestly elevated BNP values that fall in the "unlikely" range by standard cutoffs.

Back to Table of Contents

BNP vs. NT-proBNP: Choosing the Right Test

Both assays are validated and clinically reliable for diagnosing acute heart failure. The choice between them is often determined by which analyzer a hospital has available, but understanding their differences is essential for correct interpretation.

Comparison of Key Properties

Clinical Bottom Line on Test Selection

Use whichever assay your institution runs — do not order both simultaneously (it creates interpretive confusion and adds cost). For patients on sacubitril/valsartan (Entresto), always use NT-proBNP because BNP will be artifactually elevated. For patients with advanced CKD (eGFR <30 mL/min), both tests will be elevated, but BNP may be slightly easier to interpret because it is less renally cleared. For serial monitoring, stick with the same assay throughout a patient's care — switching between BNP and NT-proBNP mid-course invalidates trend interpretation.

Back to Table of Contents

Using BNP to Diagnose Acute Heart Failure

The landmark application of BNP testing was its validation in the emergency diagnosis of acute dyspnea. The Breathing Not Properly Multinational Study (Maisel et al., 2002, PMID 12124404) enrolled 1,586 patients presenting to emergency departments with acute dyspnea. It demonstrated that BNP measurement added diagnostic accuracy beyond clinical judgment alone and could rapidly stratify patients by heart failure probability. A BNP below 100 pg/mL had a negative predictive value of 96% for ruling out heart failure — meaning physicians could confidently attribute the dyspnea to a pulmonary cause without immediately pursuing an echocardiogram.

Differential Diagnosis of Dyspnea: Where BNP Fits

Acute dyspnea has a broad differential including acute decompensated heart failure (ADHF), COPD exacerbation, asthma, pneumonia, pulmonary embolism, and anxiety. Clinicians use BNP as a rapid screening tool to immediately stratify towards or away from a cardiac cause:

• BNP <100 pg/mL: Cardiac dyspnea (HF) is very unlikely. Focus workup on pulmonary causes, PE, or musculoskeletal causes.
• BNP 100–400 pg/mL: Indeterminate. Could reflect mild/treated HF, HF with preserved ejection fraction (HFpEF), right heart strain from PE, cor pulmonale, or elevated BNP from a non-HF cause (see below). Echocardiogram is the next step.
• BNP >400 pg/mL: ADHF is the most likely diagnosis. Initiate diuretic therapy and pursue echocardiogram to characterize systolic vs. diastolic dysfunction.

Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF — also called diastolic heart failure — is increasingly common and diagnostically challenging because the ejection fraction is normal (≥50%) on echocardiogram. BNP levels in HFpEF are often lower than in heart failure with reduced ejection fraction (HFrEF), but they are still typically elevated above the 100 pg/mL threshold during acute decompensation. Clinicians must not use a BNP in the 100–300 pg/mL range to exclude HFpEF in a clinically suggestive presentation. The PRIDE study (Januzzi et al., 2005, PMID 15820167) showed NT-proBNP performed well for HFpEF diagnosis when age-stratified cutoffs were applied.

Acute Flash Pulmonary Edema — A Special Case

In acute severe mitral regurgitation (e.g., from ruptured chordae tendineae or acute MI with papillary muscle rupture), flash pulmonary edema can develop within minutes. BNP may be paradoxically normal or only mildly elevated in the first few hours because ventricular wall stress has not yet had time to stimulate adequate BNP synthesis. This is one situation where clinical presentation, chest X-ray, and emergent echocardiography must drive management rather than waiting for BNP to rise.

Back to Table of Contents

Non-Heart-Failure Causes of Elevated BNP

Clinicians must recognize that an elevated BNP is not synonymous with heart failure. Many conditions cause elevated BNP through mechanisms of ventricular wall stress, impaired clearance, or inflammatory cytokine-driven BNP gene upregulation.

Cardiac Conditions (Non-HF)

• Atrial fibrillation: AF causes elevated BNP even without structural heart disease, likely from atrial stretch and associated neurohumoral activation. BNP in AF patients is typically 2–3× normal but rarely exceeds 400 pg/mL without concurrent HF.
• Acute myocardial infarction: Myocardial necrosis and resulting wall motion abnormalities cause BNP to rise within 24 hours of MI. The peak BNP post-MI correlates with infarct size and left ventricular dysfunction severity.
• Myocarditis: Inflammatory injury to cardiomyocytes causes acute BNP elevation that mirrors the degree of ventricular dysfunction.
• Hypertrophic cardiomyopathy: Chronically elevated filling pressures and outflow obstruction raise BNP. Values are often in the 200–600 pg/mL range at baseline.
• Cardiac tamponade and constrictive pericarditis: External pressure on the ventricles increases wall stress signals.

Pulmonary and Vascular Conditions

• Pulmonary embolism: Massive PE causing acute right ventricular strain elevates BNP substantially — often >400 pg/mL. BNP >90 pg/mL in PE predicts adverse in-hospital outcomes (RV dysfunction, need for thrombolysis). This is a key source of false positives in the ED dyspnea workup.
• Pulmonary arterial hypertension (PAH): Chronic right heart pressure overload causes persistent BNP elevation. Serial BNP is used in clinical trials as an endpoint for PAH therapy response.
• ARDS: Severe acute lung injury with hypoxia causes right ventricular stress and cytokine-mediated BNP release.

Systemic Conditions

• Chronic kidney disease and ESRD: NT-proBNP rises steeply with declining GFR because of reduced renal clearance. Dialysis patients typically have NT-proBNP levels 5–10× the normal upper limit even in the absence of HF. Higher NT-proBNP cutoffs (>1,200 pg/mL for rule-in) have been proposed for patients on hemodialysis.
• Sepsis and critical illness: Septic cardiomyopathy and the cytokine storm of critical illness (particularly interleukin-6 and TNF-alpha) stimulate BNP gene expression in cardiomyocytes even without primary cardiac dysfunction.
• Thyrotoxicosis: Excess thyroid hormone increases cardiac output and heart rate, inducing volume and pressure loading of the ventricles and elevating BNP.
• High-altitude exposure: Hypoxia causes pulmonary vasoconstriction and right ventricular strain, raising BNP in climbers ascending above 4,500 meters.
• Liver cirrhosis with ascites: Portal hypertension with splanchnic vasodilation increases effective cardiac output and wall stress, elevating BNP.

Vasan et al. (2002, PMID 12132156) showed in the Framingham Heart Study that natriuretic peptides are elevated in community-dwelling individuals with asymptomatic left ventricular hypertrophy and systolic dysfunction, reinforcing that BNP elevation can reflect subclinical cardiac disease long before overt HF symptoms appear.

Back to Table of Contents

When BNP Is Falsely Low

Just as important as recognizing false positives is understanding when BNP may be falsely reassuring — that is, when it falls below diagnostic thresholds despite clinically significant heart failure being present.

Obesity — the Most Important Pitfall

The single most clinically significant cause of falsely low BNP is obesity. Multiple studies — most importantly the analysis by Mehra et al. (2004, PMID 15120817) — demonstrated that adipose tissue contains natriuretic peptide clearance receptors (NPR-C) that actively remove BNP from the circulation. Obese patients with confirmed systolic heart failure have BNP values 40–50% lower than lean patients with equivalent hemodynamic severity. The clinical implication is direct: do not use the standard 100 pg/mL BNP rule-out threshold in obese patients. An obesity-corrected cutoff of approximately 54 pg/mL maintains acceptable negative predictive value in this population.

NT-proBNP is similarly suppressed in obesity, though the mechanism is less well characterized — adipose tissue may also produce humoral factors that downregulate cardiac BNP gene expression.

Early or Compensated Heart Failure

Patients with mild, stable, well-compensated chronic heart failure who are on optimal therapy — particularly RAAS inhibitors and beta-blockers — may have BNP levels below 100 pg/mL when they are hemodynamically stable. BNP reflects real-time wall stress; when therapy is working, BNP falls to near-normal even though the underlying structural heart disease remains. This is not a false negative — it is BNP doing its job as a real-time indicator of hemodynamic load.

Flash Pulmonary Edema from Acute Valvular Catastrophe

As noted above, in the setting of sudden severe mitral or aortic regurgitation, the ventricle has not had time to mount a full BNP response within the first 2–4 hours. BNP drawn in the first hour of acute presentation may be misleadingly low. Repeat measurement 6–12 hours later will typically show a dramatic rise.

Patients on Sacubitril/Valsartan (Entresto)

Sacubitril inhibits neprilysin, raising BNP — but in the context of effective therapy, the elevated BNP does not reflect worsening heart failure. Conversely, NT-proBNP (which is not degraded by neprilysin) may actually decrease on effective sacubitril/valsartan therapy. This pharmacological interference does not cause a false low per se, but it underscores why these patients require NT-proBNP rather than BNP for accurate monitoring.

Back to Table of Contents

Prognostic Value and Serial Monitoring in Heart Failure

BNP and NT-proBNP are among the most powerful prognostic biomarkers in cardiovascular medicine. Across large cohort studies and randomized trials, higher levels at hospital admission for acute decompensated heart failure independently predict:

• Longer length of hospital stay
• Higher 30-day and 1-year mortality
• Higher risk of HF re-hospitalization within 60 days
• Need for ICU-level care, mechanical circulatory support, or cardiac transplantation evaluation

Predischarge BNP as a Discharge Safety Check

Logeart et al. (2004, PMID 14975475) showed in a key study of 190 patients hospitalized for decompensated HF that predischarge BNP was the strongest predictor of 6-month re-admission and death — stronger than clinical signs of congestion or NYHA functional class at discharge. Patients discharged with BNP still >700 pg/mL had a 2.5-fold higher risk of adverse events within 6 months compared with those discharged with BNP <350 pg/mL. Many centers now use a predischarge BNP or NT-proBNP as a discharge safety criterion for ADHF.

NT-proBNP-Guided Therapy Trials

Several trials have examined whether titrating heart failure therapy to achieve a target NT-proBNP level improves outcomes, compared with usual symptom-guided care:

• PRIMA trial (Troughton et al., 2000, PMID 10791374): The original pilot trial showing NT-proBNP-guided therapy reduced hospitalizations and cardiovascular events in patients with systolic HF.
• SIGNAL-HF trial: Confirmed benefit of NT-proBNP-guided therapy in outpatients with chronic HFrEF.
• GUIDE-IT trial (Felker et al., 2017, PMID 29096801): The largest US trial (894 patients); NT-proBNP-guided therapy did not reduce the primary composite outcome vs. usual care in a well-treated contemporary population. The trial highlighted that in patients already on guideline-directed therapy, additional NT-proBNP-titrated intensification may have limits.

The current ACC/AHA guidelines (2022 HF guidelines) give a Class IIa recommendation for natriuretic peptide-guided therapy to reduce HF hospitalization in select outpatients with HFrEF who can achieve a target NT-proBNP level. Januzzi et al. (2011, PMID 22018299) demonstrated that achieving NT-proBNP below 1,000 pg/mL with intensified therapy was associated with 28% fewer HF events compared with patients who failed to achieve this target.

Community Screening with BNP

Vasan et al. (2002, PMID 12215132) demonstrated in the Framingham Heart Study that natriuretic peptides could identify community-dwelling individuals with left ventricular hypertrophy and systolic dysfunction before any symptoms appeared. This raised the possibility of BNP as a population screening tool for subclinical heart disease — an area of ongoing investigation in primary prevention cardiology.

Sex and Hormonal Influences

Lam et al. (2011, PMID 21798424) analyzed natriuretic peptide levels across sex and hormone status in large community cohorts. Women have consistently higher BNP and NT-proBNP levels than men at any given degree of cardiac pathology, even after adjusting for body size and renal function. Estrogen upregulates BNP gene expression, while testosterone suppresses it. Post-menopausal women — particularly those not on hormone replacement — have intermediate values. These differences affect diagnostic cutoff interpretation, though sex-specific thresholds are not yet universally adopted in clinical guidelines.

BNP in CKD: Separating Cardiac from Renal Contribution

McCullough et al. (2003, PMID 12612977) specifically analyzed BNP values in the Breathing Not Properly trial stratified by renal function. Even in patients with advanced CKD (serum creatinine >2.0 mg/dL), a BNP <100 pg/mL still had high negative predictive value for ruling out HF, and a BNP >200 pg/mL in CKD patients had positive predictive value for HF exceeding 90%. BNP's renal-independent clearance (via NPR-C and neprilysin) makes it less confounded by kidney disease than NT-proBNP, though absolute values are still modestly elevated in CKD. Anwaruddin et al. (2006, PMID 16386670) confirmed that NT-proBNP requires GFR-based interpretation: in ESRD patients, NT-proBNP values of 2,000–4,000 pg/mL can be "normal" for that population, and only values substantially above population-based CKD-specific norms should prompt concern for superimposed HF.

Back to Table of Contents

Key Research and Citations

The following peer-reviewed studies established the diagnostic and prognostic value of BNP and NT-proBNP in clinical practice.

1. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167. PMID 12124404
2. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948–954. PMID 15820167
3. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc. 2005;80(8):1029–1036. PMID 16092580
4. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881–1889. PMID 22018299
5. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43(4):635–641. PMID 14975475
6. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA. 2002;288(10):1252–1259. PMID 12215132
7. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571–579. PMID 12612977
8. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43(9):1590–1595. PMID 15120817
9. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126–1130. PMID 10791374
10. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement. J Am Coll Cardiol. 2006;47(1):91–97. PMID 16386670
11. Lam CS, Lyass A, Kraigher-Krainer E, et al. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol. 2011;58(6):618–626. PMID 21798424
12. Felker GM, Anstrom KJ, Adams KF, et al. Natriuretic peptide-guided management in chronic heart failure. J Am Coll Cardiol. 2017;70(19):2357–2366. PMID 29096801

Back to Table of Contents

Connections

• Cardiac Troponin — Myocardial Injury Marker
• Troponin Test
• BNP/NT-proBNP (Legacy Page)
• Kidney Function Tests
• Complete Blood Count (CBC)
• Comprehensive Metabolic Panel
• Inflammatory Markers
• High-Sensitivity CRP
• Coagulation Panel
• Cortisol Test
• All Lab Tests
• Cardiology Diseases

Back to Table of Contents

Featured Videos